Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
NQO1 is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a cytoplasmic 2-electron reductase. This FAD-binding protein forms homodimers and reduces quinones to hydroquinones. This protein's enzymatic activity prevents the one electron reduction of quinones that results in the production of radical species. Mutations in this gene have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of this protein has been seen in many tumors and is also associated with Alzheimer's disease (AD). Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
Immortalisation of a human diploid fibroblast cell strain: a DT-diaphorase paradox. Kuehl BL, Brezden CB, Traver RD, Siegel D, Ross D, Renzing J, Rauth AM. The British journal of cancer. Supplement. 1996 27:S19-22. (WB; Human)
Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Siegel D, Ross D. Free radical biology & medicine. 2000 29:246-53.
Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Molecular pharmacology. 2001 59:263-8. (WB, IP; Human)
Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. Anwar A, Dehn D, Siegel D, Kepa JK, Tang LJ, Pietenpol JA, Ross D. The Journal of biological chemistry. 2003 278:10368-73. (WB, IP; Human)
Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Zhang J, Schulz WA, Li Y, Wang R, Zotz R, Wen D, Siegel D, Ross D, Gabbert HE, Sarbia M. Carcinogenesis. 2003 24:905-9. (IHC-P; Human)
trans-Stilbene oxide induces expression of genes involved in metabolism and transport in mouse liver via CAR and Nrf2 transcription factors. Slitt AL, Cherrington NJ, Dieter MZ, Aleksunes LM, Scheffer GL, Huang W, Moore DD, Klaassen CD. Molecular pharmacology. 2006 69:1554-63.
5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo. Dehn DL, Siegel D, Zafar KS, Reigan P, Swann E, Moody CJ, Ross D. Molecular cancer therapeutics. 2006 5:1702-9. (WB; Human)
Dietary flaxseed enhances antioxidant defenses and is protective in a mouse model of lung ischemia-reperfusion injury. Lee JC, Bhora F, Sun J, Cheng G, Arguiri E, Solomides CC, Chatterjee S, Christofidou-Solomidou M. American journal of physiology. Lung cellular and molecular physiology. 2008 294:L255-65.
Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus disease. Cho HY, Imani F, Miller-DeGraff L, Walters D, Melendi GA, Yamamoto M, Polack FP, Kleeberger SR. American journal of respiratory and critical care medicine. 2009 179:138-50.
Effect of tumor necrosis factor-alpha on estrogen metabolism and endometrial cells: potential physiological and pathological relevance. Salama SA, Kamel MW, Diaz-Arrastia CR, Xu X, Veenstra TD, Salih S, Botting SK, Kumar R. The Journal of clinical endocrinology and metabolism. 2009 94:285-93.
Nitric oxide activation of Keap1/Nrf2 signaling in human colon carcinoma cells. Li CQ, Kim MY, Godoy LC, Thiantanawat A, Trudel LJ, Wogan GN. Proceedings of the National Academy of Sciences of the United States of America. 2009 106:14547-51.
Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. Malhotra D, Thimmulappa R, Vij N, Navas-Acien A, Sussan T, Merali S, Zhang L, Kelsen SG, Myers A, Wise R, Tuder R, Biswal S. American journal of respiratory and critical care medicine. 2009 180:1196-207.
Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ, Wistuba II. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 16:3743-53. (IHC-P; Human)
Antioxidant components of naturally-occurring oils exhibit marked anti-inflammatory activity in epithelial cells of the human upper respiratory system. Gao M, Singh A, Macri K, Reynolds C, Singhal V, Biswal S, Spannhake EW. Respiratory research. 2011 12:92.
Histone deacetylase inhibition activates transcription factor Nrf2 and protects against cerebral ischemic damage. Wang B, Zhu X, Kim Y, Li J, Huang S, Saleem S, Li RC, Xu Y, Dore S, Cao W. Free radical biology & medicine. 2012 52:928-36. (WB; Mouse)